{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T18:02:31Z","timestamp":1788631351658,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fabry disease is an X-linked lysosomal storage disease caused by a mutation in the galactosidase alpha (GLA) gene. Despite advances in therapeutic technologies, the lack of humanized experimental models of Fabry disease has limited the development of new therapies to cure the disease. Herein, we modeled Fabry disease using human inducible pluripotent stem cell (iPSC)-derived kidney organoids and the CRISPR\u2013Cas9 genome-editing system. GLA-mutant human kidney organoids revealed deformed podocytes and tubular cells with accumulation of globotriaosylceramide (Gb3). Ultrastructural analysis showed abundant electron-dense granular deposits and electron-dense lamellate lipid-like deposits that formed concentric bodies (zebra bodies) in the cytoplasm of podocytes and tubules. The oxidative stress level was increased in GLA-mutant kidney organoids, and the increase was accompanied by apoptosis. Enzyme replacement treatment (ERT) with recombinant human \u03b1-Gal A decreased the Gb3 accumulation and oxidative stress, which resulted in amelioration of the deformed cellular structure of the GLA-mutant kidney organoids. Transcription profile analyses showed decreased glutathione (GSH) metabolism in GLA-mutant kidney organoids. GSH replacement treatment decreased oxidative stress and attenuated the structural deformity of the GLA-mutant kidney organoids. GSH treatment also increased the expression of podocyte and tubular markers and decreased apoptosis. In conclusion, GLA-mutant kidney organoids derived from human iPSCs are valuable tools for studying the mechanisms and developing novel therapeutic alternatives for Fabry disease.<\/jats:p>","DOI":"10.1038\/s12276-021-00683-y","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T18:52:10Z","timestamp":1634323930000},"page":"1580-1591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Human kidney organoids reveal the role of glutathione in Fabry disease"],"prefix":"10.1038","volume":"53","author":[{"given":"Jin Won","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Ah","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Jin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7993-9701","authenticated-orcid":false,"given":"Tae-Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Kyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"key":"683_CR1","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","volume":"276","author":"RO Brady","year":"1967","unstructured":"Brady, R. O. et al. Enzymatic defect in Fabry\u2019s disease: ceramidetrihexosidase deficiency. N. Engl. J. Med. 276, 1163\u20131167 (1967).","journal-title":"N. Engl. J. Med."},{"key":"683_CR2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1471-2369-15-72","volume":"15","author":"S Waldek","year":"2014","unstructured":"Waldek, S. & Feriozzi, S. Fabry nephropathy: a review\u2013how can we optimize the management of Fabry nephropathy? BMC Nephrol. 15, 72 (2014).","journal-title":"BMC Nephrol."},{"key":"683_CR3","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","volume":"372","author":"YA Zarate","year":"2008","unstructured":"Zarate, Y. A. & Hopkin, R. J. Fabry\u2019s disease. Lancet 372, 1427\u20131435 (2008).","journal-title":"Lancet"},{"key":"683_CR4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","volume":"30","author":"C Eng","year":"2007","unstructured":"Eng, C. et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J. Inherit. Metab. Dis. 30, 184\u2013192 (2007).","journal-title":"J. Inherit. Metab. Dis."},{"key":"683_CR5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ymgme.2007.08.108","volume":"4","author":"W Wilcox","year":"2007","unstructured":"Wilcox, W. & Germain, D. 103 Females with X-linked Fabry disease frequently have significant organ involvement. Mol. Genet. Metab. 4, 32 (2007).","journal-title":"Mol. Genet. Metab."},{"key":"683_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00441-017-2609-9","volume":"369","author":"\u00d8 Eikrem","year":"2017","unstructured":"Eikrem, \u00d8. et al. Pathomechanisms of renal Fabry disease. Cell Tissue Res. 369, 53\u201362 (2017).","journal-title":"Cell Tissue Res."},{"key":"683_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-017-0571-0","volume":"18","author":"PDM de Menezes Neves","year":"2017","unstructured":"de Menezes Neves, P. D. M. et al. Ultrastructural deposits appearing as \u201czebra bodies\u201d in renal biopsy: Fabry disease?\u2013comparative case reports. BMC Nephrol. 18, 1\u20137 (2017).","journal-title":"BMC Nephrol."},{"key":"683_CR8","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/sj.ki.5002677","volume":"73","author":"FC Fervenza","year":"2008","unstructured":"Fervenza, F. C., Torra, R. & Lager, D. Fabry disease: an underrecognized cause of proteinuria. Kidney Int. 73, 1193\u20131199 (2008).","journal-title":"Kidney Int."},{"key":"683_CR9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","volume":"81","author":"MH Branton","year":"2002","unstructured":"Branton, M. H. et al. Natural history of Fabry renal disease: influence of \u03b1-galactosidase A activity and genetic mutations on clinical course. Medicine 81, 122\u2013138 (2002).","journal-title":"Medicine"},{"key":"683_CR10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.12688\/f1000research.13708.1","volume":"7","author":"S McCloskey","year":"2018","unstructured":"McCloskey, S., Brennan, P. & Sayer, J. A. Variable phenotypic presentations of renal involvement in Fabry disease: a case series. F1000Research 7, 356 (2018).","journal-title":"F1000Research"},{"key":"683_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"C Eng","year":"2001","unstructured":"Eng, C. et al. International Collaborative Fabry Disease Study Group: Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry\u2019s disease. N. Engl. J. Med. 345, 9\u201316 (2001).","journal-title":"N. Engl. J. Med."},{"key":"683_CR12","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann, R. et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285, 2743\u20132749 (2001).","journal-title":"JAMA"},{"key":"683_CR13","first-page":"807","volume":"32","author":"R Skrunes","year":"2017","unstructured":"Skrunes, R., Svarstad, E., Kampevold Larsen, K., Leh, S. & T\u00f8ndel, C. Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients. Nephrol. Dial. Transpl. 32, 807\u2013813 (2017).","journal-title":"Nephrol. Dial. Transpl."},{"key":"683_CR14","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1681\/ASN.2018070740","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders, M. et al. Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease. J. Am. Soc. Nephrol. 29, 2879\u20132889 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"683_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9715","volume":"6","author":"BS Freedman","year":"2015","unstructured":"Freedman, B. S. et al. Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids. Nat. Commun. 6, 8715 (2015).","journal-title":"Nat. Commun."},{"key":"683_CR16","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1002\/stem.2707","volume":"35","author":"YK Kim","year":"2017","unstructured":"Kim, Y. K. et al. Gene\u2010edited human kidney organoids reveal mechanisms of disease in podocyte development. Stem Cells 35, 2366\u20132378 (2017).","journal-title":"Stem Cells"},{"key":"683_CR17","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3904\/kjim.2018.198","volume":"33","author":"YK Kim","year":"2018","unstructured":"Kim, Y. K., Nam, S. A. & Yang, C. W. Applications of kidney organoids derived from human pluripotent stem cells. Korean J. Intern. Med. 33, 649 (2018).","journal-title":"Korean J. Intern. Med."},{"key":"683_CR18","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00418-017-1589-x","volume":"148","author":"T-R Riew","year":"2017","unstructured":"Riew, T.-R. et al. Progressive accumulation of autofluorescent granules in macrophages in rat striatum after systemic 3-nitropropionic acid: a correlative light-and electron-microscopic study. Histochem. Cell Biol. 148, 517\u2013528 (2017).","journal-title":"Histochem. Cell Biol."},{"key":"683_CR19","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fnmol.2018.00402","volume":"11","author":"T-R Riew","year":"2018","unstructured":"Riew, T.-R., Choi, J.-H., Kim, H. L., Jin, X. & Lee, M.-Y. PDGFR-\u03b2-positive perivascular adventitial cells expressing nestin contribute to fibrotic scar formation in the striatum of 3-NP intoxicated rats. Front. Mol. Neurosci. 11, 402 (2018).","journal-title":"Front. Mol. Neurosci."},{"key":"683_CR20","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1681\/ASN.2005040383","volume":"16","author":"L Shu","year":"2005","unstructured":"Shu, L., Murphy, H. S., Cooling, L. & Shayman, J. A. An in vitro model of Fabry disease. J. Am. Soc. Nephrol. 16, 2636\u20132645 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"683_CR21","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/MNH.0b013e32833aa4ac","volume":"19","author":"IA Bobulescu","year":"2010","unstructured":"Bobulescu, I. A. Renal lipid metabolism and lipotoxicity. Curr. Opin. Nephrol. Hy. 19, 393 (2010).","journal-title":"Curr. Opin. Nephrol. Hy."},{"key":"683_CR22","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3390\/jcm7110409","volume":"7","author":"V Ravarotto","year":"2018","unstructured":"Ravarotto, V. et al. Oxidative stress and cardiovascular-renal damage in fabry disease: Is there room for a pathophysiological involvement? J. Clin. Med. 7, 409 (2018).","journal-title":"J. Clin. Med."},{"key":"683_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cca.2017.12.033","volume":"478","author":"AP Moura","year":"2018","unstructured":"Moura, A. P., Hammerschmidt, T., Deon, M., Giugliani, R. & Vargas, C. R. Investigation of correlation of urinary globotriaosylceramide (Gb3) levels with markers of renal function in patients with Fabry disease. Clin. Chim. Acta 478, 62\u201367 (2018).","journal-title":"Clin. Chim. Acta"},{"key":"683_CR24","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/nep.12977","volume":"22","author":"GB Biancini","year":"2017","unstructured":"Biancini, G. B. et al. Globotriaosylsphingosine induces oxidative DNA damage in cultured kidney cells. Nephrology 22, 490\u2013493 (2017).","journal-title":"Nephrology"},{"key":"683_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cca.2016.07.016","volume":"461","author":"GB Biancini","year":"2016","unstructured":"Biancini, G. B. et al. Biomolecules damage and redox status abnormalities in Fabry patients before and during enzyme replacement therapy. Clin. Chim. Acta 461, 41\u201346 (2016).","journal-title":"Clin. Chim. Acta"},{"key":"683_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10565-014-9284-3","volume":"30","author":"G Negretto","year":"2014","unstructured":"Negretto, G. et al. Glycosaminoglycans can be associated with oxidative damage in mucopolysaccharidosis II patients submitted to enzyme replacement therapy. Cell Biol. Toxicol. 30, 189\u2013193 (2014).","journal-title":"Cell Biol. Toxicol."},{"key":"683_CR27","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","volume":"1822","author":"GB Biancini","year":"2012","unstructured":"Biancini, G. B. et al. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. BBA-Mol. Basis Dis. 1822, 226\u2013232 (2012).","journal-title":"BBA-Mol. Basis Dis."},{"key":"683_CR28","doi-asserted-by":"publisher","DOI":"10.1177\/2054358120985627","volume":"8","author":"CAB Silva","year":"2021","unstructured":"Silva, C. A. B., Moura-Neto, J. A., Dos Reis, M. A., Vieira Neto, O. M. & Barreto, F. C. Renal Manifestations of Fabry Disease: A Narrative Review. Can. J. Kidney Health Dis. 8, 2054358120985627 (2021).","journal-title":"Can. J. Kidney Health Dis."},{"key":"683_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj3600001","volume":"360","author":"D Sheehan","year":"2001","unstructured":"Sheehan, D., Meade, G., Foley, V. M. & Dowd, C. A. Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily. Biochem. J. 360, 1\u201316 (2001).","journal-title":"Biochem. J."},{"key":"683_CR30","doi-asserted-by":"publisher","first-page":"498","DOI":"10.5606\/ArchRheumatol.2018.6595","volume":"33","author":"G Siming","year":"2018","unstructured":"Siming, G., Honglin, Z., Xiaoxia, Z. & Hui, L. Cathepsin G and its role in inflammation and autoimmune diseases. Arch. Rheumatol. 33, 498 (2018).","journal-title":"Arch. Rheumatol."},{"key":"683_CR31","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/jcp.22532","volume":"226","author":"J Yin","year":"2011","unstructured":"Yin, J., Thomas, F., Lang, J. C. & Chaum, E. Modulation of oxidative stress responses in the human retinal pigment epithelium following treatment with vitamin C. J. Cell. Physiol. 226, 2025\u20132032 (2011).","journal-title":"J. Cell. Physiol."},{"key":"683_CR32","first-page":"220","volume":"53","author":"WR Pearson","year":"1993","unstructured":"Pearson, W. R. et al. Identification of class-mu glutathione transferase genes GSTM1-GSTM5 on human chromosome 1p13. Am. J. Hum. Genet. 53, 220 (1993).","journal-title":"Am. J. Hum. Genet."},{"key":"683_CR33","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. P. Natl A. Sci. Usa. 102, 15545\u201315550 (2005).","journal-title":"P. Natl A. Sci. Usa."},{"key":"683_CR34","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","volume":"94","author":"T Ohshima","year":"1997","unstructured":"Ohshima, T. et al. \u03b1-Galactosidase A deficient mice: a model of Fabry disease. P. Natl A. Sci. Usa. 94, 2540\u20132544 (1997).","journal-title":"P. Natl A. Sci. Usa."},{"key":"683_CR35","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.3390\/ijms22126518","volume":"22","author":"A Modrego","year":"2021","unstructured":"Modrego, A. et al. Human \u03b1-Galactosidase A mutants: priceless tools to develop novel therapies for fabry disease. Int. J. Mol. Sci. 22, 6518 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"683_CR36","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.stem.2018.04.022","volume":"22","author":"SM Czerniecki","year":"2018","unstructured":"Czerniecki, S. M. et al. High-throughput screening enhances kidney organoid differentiation from human pluripotent stem cells and enables automated multidimensional phenotyping. cell Stem cell 22, 929\u2013940 (2018). e4.","journal-title":"cell Stem cell"},{"key":"683_CR37","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0731-7085(02)00594-0","volume":"31","author":"X Guan","year":"2003","unstructured":"Guan, X., Hoffman, B., Dwivedi, C. & Matthees, D. P. A simultaneous liquid chromatography\/mass spectrometric assay of glutathione, cysteine, homocysteine and their disulfides in biological samples. J. Pharm. Biomed. 31, 251\u2013261 (2003).","journal-title":"J. Pharm. Biomed."},{"key":"683_CR38","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1093\/ndt\/gfh266","volume":"19","author":"F Santangelo","year":"2004","unstructured":"Santangelo, F., Witko-Sarsat, V., Dr\u00fceke, T. & Descamps-Latscha, B. Restoring glutathione as a therapeutic strategy in chronic kidney disease. Nephrol. Dial. Transpl. 19, 1951\u20131955 (2004).","journal-title":"Nephrol. Dial. Transpl."},{"key":"683_CR39","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.taap.2004.10.004","volume":"204","author":"LH Lash","year":"2005","unstructured":"Lash, L. H. Role of glutathione transport processes in kidney function. Toxicol. Appl. Pharm. 204, 329\u2013342 (2005).","journal-title":"Toxicol. Appl. Pharm."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-021-00683-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-021-00683-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-021-00683-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T08:02:57Z","timestamp":1636012977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-021-00683-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["683"],"URL":"https:\/\/doi.org\/10.1038\/s12276-021-00683-y","relation":{},"ISSN":["1226-3613","2092-6413"],"issn-type":[{"value":"1226-3613","type":"print"},{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"31 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}